A new ecosystem that combines at-home blood biomarker testing with digital cognitive assessments has been validated in a groundbreaking study, promising to revolutionize the diagnosis and treatment of Alzheimer’s disease.
According to researchers, this system could reduce the time from symptom onset to care by 4.5 years, significantly increasing access to early detection and treatment for millions of Americans affected by the disease. The system, developed by Neurogen, uses a non-invasive blood collection method called TASSO and advanced digital cognitive testing.
The study, which involved over 450 participants aged 50-67, found that the TASSO method identified elevated biomarkers with 88% accuracy, meeting performance requirements for Alzheimer’s disease triaging. The system also reduced the time from cognitive concerns to intervention by four years, compared to a standard timeline of three to six years.
Neurogen’s mission is to provide equal access to cutting-edge technology for early detection and treatment of Alzheimer’s disease, with the ultimate goal of improving patient outcomes and quality of life. With its online ecosystem currently in beta test and preparing for national launch, this breakthrough system has the potential to transform how Alzheimer’s and cognitive decline are detected and managed.
Source: https://hitconsultant.net/2025/07/28/neurogen-biomarking-virtual-care-ecosystem-cuts-time-to-alzheimers-intervention-by-4-5-years